Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.

导出 OA

翻译打印收藏纠错

作者： Kimiyuki,Ikeda ^[1] ; Hirofumi,Chiba ^[2] ; Hirotaka,Nishikiori ^[1] ; Arata,Azuma ^[3] ; Yasuhiro,Kondoh ^[4] ; Takashi,Ogura ^[5] ; Yoshio,Taguchi ^[6] ; Masahito,Ebina ^[7] ; Hiroki,Sakaguchi ^[8] ; Shogo,Miyazawa ^[8] ; Moritaka,Suga ^[9] ; Yukihiko,Sugiyama ^[10] ; Toshihiro,Nukiwa ^[11] ; Shoji,Kudoh ^[12] ; Hiroki,Takahashi ^[1] ; Pirfenidone Clinical Study Group in Japan

作者单位： Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, South 1, West 16, Sapporo, 060-8543, Japan. ^[1] Department of Respiratory Medicine and Allergology, School of Medicine, Sapporo Medical University, South 1, West 16, Sapporo, 060-8543, Japan. hchiba@sapmed.ac.jp. ^[2] Nippon Medical School, Tokyo, Japan. ^[3] Tosei General Hospital, Seto, Japan. ^[4] Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan. ^[5] Tenri Hospital, Tenri, Japan. ^[6] Tohoku Medical and Pharmaceutical University, Sendai, Japan. ^[7] Shionogi & Co., Ltd, Osaka, Japan. ^[8] Saiseikai Kumamoto Hospital, Kumamoto, Japan. ^[9] Jichi Medical University, Shimotsuke, Japan. ^[10] Tohoku University, Sendai, Japan. ^[11] Japan Anti-Tuberculosis Association, Tokyo, Japan. ^[12]

关键词 Biomarker Idiopathic pulmonary fibrosis Pirfenidone Surfactant protein D